COMPARISON OF THE CARDIOVASCULAR AND NEURAL ACTIVITY OF ENDOTHELIN-1, ENDOTHELIN-2, ENDOTHELIN-3 AND RESPECTIVE PROENDOTHELINS - EFFECTS OF PHOSPHORAMIDON AND THIORPHAN

被引:13
作者
MATTERA, GG
EGLEZOS, A
RENZETTI, AR
MIZRAHI, J
机构
[1] Pharmacology Department, Laboratori Guidotti SpA, Pisa, 56122, Via Livornese 402, San Piero a Grado
关键词
ENDOTHELINS; PROENDOTHELINS; PHOSPHORAMIDON; THIORPHAN; MEAN ARTERIAL PRESSURE; RAT VAS DEFERENS;
D O I
10.1111/j.1476-5381.1993.tb13813.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 In the anaesthetized, ganglion-blocked rat, intravenous boluses of endothelin-1, endothelin-2 and endothelin-3 induced a transient hypotensive effect followed by a potent long lasting pressor response (ED50 mmHg: 0.72 +/- 0.05, 1.8 +/- 0.2 and 2.7 +/- 0.3 nmol kg-1, respectively). The maximal effect for the three peptides was of a similar order of magnitude (DELTAMAP: 84 to 89 mmHg). Neither of these effects was influenced by phosphoramidon or thiorphan (10 mg kg-1, i.v.). 2 Intravenously administered big-endothelin-1 and -2 induced a transient (1-2 min) hypotension followed by a potent long lasting (> 25 min) vasopressor effect (ED50 mmHg: 1.8 +/- 0.2 and 6.7 +/- 0.4 nmol kg-1, respectively), with a similar maximal activity (DELTA MAP: 85 +/- 4 and 81 +/- 2.4 mmHg, respectively). The onset of the big-endothelin-1 vasopressor effect was more rapid (5 - 6 min) than that of big-endothelin-2 (10-13 min). Big-endothelin-3 was found to induce only a potent, long lasting (> 35 min) hypertension, with a maximal effect of 75 +/- 4.6 mmHg at 10 nmol kg-1 and an ED50 mmHg of 6.5 +/- 0.4 nmol kg-1. The onset of this effect was much slower (20-25 min) than that of the other proendothelins. Pressor responses induced by big-endothelin-1, -2 and -3 (3, 15 and 10 nmol kg-1, respectively) were markedly reduced (60, 80 and 100%) in the presence of phosphoramidon (10 mg kg-1, i.v.). Thiorphan (10 mg kg-1, i.v.) did not inhibit the effects of big-endothelin-1, -2 and -3. 3 In the electrically stimulated rat vas deferens, endothelin-1 and -2 were found to be equipotent enhancers of the twitch response (EC100%: 4.0 +/- 0.4 nm and 7.9 +/- 4.8 nm, respectively), both about 3-4 fold as active as endothelin-3 (EC100%: 19 +/- 2.5 nm). Endothelin-1 and -3 showed a comparable maximal stimulatory effect (E(max): 296 +/- 30 and 262 +/- 24%) while endothelin-2 was less active (E(max): 194 +/- 30%). 4 Big-endothelin-1 and -2 were potent enhancers of the twitch reponse too (EC100%: 10.0 +/- 2.6 nm and 21.6 +/- 3.2 nm, respectively), with a comparable maximal stimulatory effect (E(max): 254 +/- 22 and 264 +/- 24%). Big-endothelin-3 was found to be less potent (EC100%: 275 +/- 21 nm), but retained a marked potentiating effect (E(max): 200 +/- 38%). Phosphoramidon, but not thiorphan, concentration-dependently (10 and 100 muM) reduced big-endothelin-1 (58 and 86% respectively) and big-endothelin-2 (21 and 56%) -mediated responses. Conversely, the big-endothelin-3 effect was reduced by phosphoramidon only at 100 muM (-70%), while thiorphan acts concentration-dependently (31 and 71% at 10 and 100 muM respectively); thus, in the rat vas deferens, big-endothelin-1 and -2 were as potent as their corresponding endothelins, while big-endothelin-3 was about 20 times less potent than endothelin-3. 5 The increasing effect of endothelin-2 (194 +/- 30% over baseline) was significantly enhanced by either 10 muM phosphoramidon (277 +/- 42%) or thiorphan (318 +/- 15%). The endothelin-1 and endothelin-3-mediated twitch enhancement was not affected by the two protease inhibitors (10 muM). 6 These results suggest that in vivo big-endothelin-1, -2 and -3, are processed through a similar phosphoramidon-sensitive enzymatic pathway although with different apparent affinity. This enzymatic process is probably attributable to a neutral endoprotease, distinct from neutral-endopeptidase 24.11 (NEP). On the other hand, a NEP-like enzymatic activity may be involved, in the rat vas deferens, in the activation of big-endothelin-3 to endothelin-3 and in the metabolism of endothelin-2, but not of endothelin-I or endothelin-3.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 41 条
[1]   CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR [J].
ARAI, H ;
HORI, S ;
ARAMORI, I ;
OHKUBO, H ;
NAKANISHI, S .
NATURE, 1990, 348 (6303) :730-732
[2]  
DEGOUVILLE ACL, 1991, J CARDIOVASC PHARM, V17, pS362
[3]   HUMAN BIG ENDOTHELIN RELEASES PROSTACYCLIN INVIVO AND INVITRO THROUGH A PHOSPHORAMIDON-SENSITIVE CONVERSION TO ENDOTHELIN-1 [J].
DORLEANSJUSTE, P ;
LIDBURY, PS ;
TELEMAQUE, S ;
WARNER, TD ;
VANE, JR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 :S251-S255
[4]   DIFFERENT PHARMACOLOGICAL PROFILES OF BIG-ENDOTHELIN-3 AND BIG-ENDOTHELIN-1 INVIVO AND INVITRO [J].
DORLEANSJUSTE, P ;
TELEMAQUE, S ;
CLAING, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (02) :440-444
[5]   RESPONSES TO ENDOTHELIN-1, HUMAN PROENDOTHELIN (1-38) AND PORCINE PROENDOTHELIN (1-39) IN THE RAT ON INTRAVENOUS ADMINISTRATION AND IN THE BLOOD PERFUSED MESENTERY [J].
DOUGLAS, SA ;
HILEY, CR .
NEUROCHEMISTRY INTERNATIONAL, 1991, 18 (04) :445-454
[6]   INVITRO DEGRADATION OF ENDOTHELIN-1 BY ENDOPEPTIDASE 24.11 (ENKEPHALINASE) [J].
FAGNY, C ;
MICHEL, A ;
LEONARD, I ;
BERKENBOOM, G ;
FONTAINE, J ;
DESCHODTLANCKMAN, M .
PEPTIDES, 1991, 12 (04) :773-778
[7]   INHIBITION OF BIOLOGICAL ACTIONS OF BIG ENDOTHELIN-1 BY PHOSPHORAMIDON [J].
FUKURODA, T ;
NOGUCHI, K ;
TSUCHIDA, S ;
NISHIKIBE, M ;
IKEMOTO, F ;
OKADA, K ;
YANO, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 172 (02) :390-395
[8]   CELIAC HEMODYNAMIC-EFFECTS OF ENDOTHELIN-1, ENDOTHELIN-3, PROENDOTHELIN-1 [1-38] AND PROENDOTHELIN-3 [1-41] IN CONSCIOUS RATS [J].
GARDINER, SM ;
KEMP, PA ;
COMPTON, AM ;
BENNETT, T .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (02) :483-488
[9]   INHIBITION BY PHOSPHORAMIDON OF THE REGIONAL HEMODYNAMIC-EFFECTS OF PROENDOTHELIN-2 AND PROENDOTHELIN-3 IN CONSCIOUS RATS [J].
GARDINER, SM ;
KEMP, PA ;
BENNETT, T .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (02) :584-590
[10]   ENDOTHELIN RECEPTOR SUBTYPES AND STIMULATION OF ALDOSTERONE SECRETION [J].
GOMEZSANCHEZ, CE ;
COZZA, EN ;
FOECKING, MF ;
CHIOU, S ;
FERRIS, MW .
HYPERTENSION, 1990, 15 (06) :744-747